Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 57

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 57
---
 |     |   |  10.4 | % |
| Denali Convertible Promissory Notes*** |     |               |     305,161 |     |   |   0.1 | % |     |                |     305,161 |     |   |   0.1 | % |     |                |     305,161 |     |   |   0.1 | % |     |                |     305,161 |     |   |   0.1 | % |     |                 |     305,161 |     |   |   0.1 | % |
| Underwriters Fees Paid in Shares       |     |               |      86,625 |     |   |   0.0 | % |     |                |      86,625 |     |   |   0.0 | % |     |                |      86,625 |     |   |   0.0 | % |     |                |      86,625 |     |   |   0.0 | % |     |                 |      86,625 |     |   |   0.0 | % |
| Total Number of Shares                 |     |               | 292,886,025 |     |   | 100.0 | % |     |                | 292,875,090 |     |   | 100.0 | % |     |                | 292,864,155 |     |   | 100.0 | % |     |                | 292,853,220 |     |   | 100.0 | % |     |                 | 292,842,286 |     |   | 100.0 | % |

| * | Comprised of 29,117 public shares outstanding as of the date of this proxy statement/prospectus and assumes that the holders of 14,622 Public Units have voluntarily separated such units into their component parts prior to the Closing such that the 14,622 public shares underlying such units are available for redemption in connection with the Business Combination. |

| ** | Includes 155,000,000 shares of Semnur Common Stock held by Scilex’s wholly owned subsidiary, Scilex, Inc. (f/k/a Scilex Holding Company) and 5,000,000 shares of Semnur Common Stock contributed to Scilex Bio (which is controlled by